Lyell Immunopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYEL research report →
Companywww.lyell.com
Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
- CEO
- Lynn Seely
- IPO
- 2021
- Employees
- 300
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $392.25M
- P/E
- -1.49
- P/S
- 12653.10
- P/B
- 1.34
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -7422.58%
- Op Margin
- -618909.68%
- Net Margin
- -794858.06%
- ROE
- -85.71%
- ROIC
- -61.17%
Growth & Income
- Revenue
- $36.00K · -40.98%
- Net Income
- $-274,448,000 · 19.98%
- EPS
- $-16.06 · -1125.95%
- Op Income
- $-203,774,000
- FCF YoY
- 7.40%
Performance & Tape
- 52W High
- $45.00
- 52W Low
- $7.65
- 50D MA
- $21.29
- 200D MA
- $20.39
- Beta
- -0.06
- Avg Volume
- 90.00K
Get TickerSpark's AI analysis on LYEL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 9, 26 | Shah Smital | other | 140,000 |
| Mar 9, 26 | Shah Smital | other | 0 |
| Mar 6, 26 | ARCH Venture Partners IX, LLC | buy | 488,090 |
| Mar 6, 26 | ARCH Venture Fund XIII, L.P. | buy | 488,090 |
| Feb 11, 26 | Seely Lynn | sell | 7,455 |
| Feb 11, 26 | Hill Stephen J. | sell | 1,236 |
| Feb 11, 26 | Lee Gary K. | sell | 1,671 |
| Feb 10, 26 | Hill Stephen J. | other | 65,000 |
| Feb 9, 26 | Hill Stephen J. | other | 4,000 |
| Feb 10, 26 | Hill Stephen J. | sell | 109 |
Our LYEL Coverage
We haven't published any research on LYEL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LYEL Report →